Provided by Tiger Trade Technology Pte. Ltd.

Twist Bioscience Corp

44.50
+2.435.78%
Post-market: 44.01-0.4900-1.10%17:28 EDT
Volume:1.77M
Turnover:78.03M
Market Cap:2.72B
PE:-35.03
High:45.57
Open:44.18
Low:43.35
Close:42.07
52wk High:57.88
52wk Low:23.30
Shares:61.15M
Float Shares:59.26M
Volume Ratio:1.87
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2703
EPS(LYR):-1.2987
ROE:-16.79%
ROA:-13.49%
PB:5.97
PE(LYR):-34.27

Loading ...

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

InvestorPlace
·
Jan 27

Twist Bioscience Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

Why Twist Bioscience (TWST) Is Up 17.2% After Revenue Beat And Bullish Analyst Coverage – And What's Next

Simply Wall St.
·
Jan 17

Twist Bioscience Corp : Leerink Partners Raises Target Price to $44 From $37

THOMSON REUTERS
·
Jan 16

Twist Bioscience CFO Adam Laponis Reports Disposal of Common Shares

Reuters
·
Jan 16

Twist Bioscience President and COO Patrick John Finn Reports Disposal of Common Shares

Reuters
·
Jan 16

Assessing Twist Bioscience (TWST) Valuation After Preliminary Q1 Revenue Update

Simply Wall St.
·
Jan 16

Barclays Sticks to Its Buy Rating for Twist Bioscience (TWST)

TIPRANKS
·
Jan 13

Twist Bioscience Reports 17% Rise in Preliminary Q1 Revenue

MT Newswires Live
·
Jan 12

Twist Bioscience Showcases Growth Strategy and Biotech Solutions in New Presentation

Reuters
·
Jan 12

Twist Bioscience Corporation published an update to their financial calendar

Reuters
·
Jan 12

Twist Bioscience Corp: Total Revenue for Q1 of Fiscal 2026 Grew 17% to About $103.7 Million

THOMSON REUTERS
·
Jan 12

Press Release: Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

Dow Jones
·
Jan 12

What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?

Simply Wall St.
·
Jan 10

Twist Bioscience Corp : TD Cowen Raises Target Price to $43 From $32

THOMSON REUTERS
·
Jan 08

Twist Bioscience Corporation Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Jan 07

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

Twist Bioscience CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 18, 2025

Twist Bioscience Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 16, 2025

Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?

Simply Wall St.
·
Dec 05, 2025